Trial · NCT02771977
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients With Progression of AKI OR Dialysis OR Death | 14 days from Randomization | Progression of AKI is defined by an increase in KDIGO creatinine stage from time of randomization to the present. Dialysis is defined by the receipt of hemodialysis, continuous renal replacement therapy or peritoneal dialysis. Isolated ultrafiltration treatments will not be included. Mortality will be determined from hospital records. |
| Secondary | Percentage of Patients for Whom Any One of the Targeted Medications is Discontinued | Assessed within 24 hours from randomization | The Percentage of patients for whom the targeted agent was discontinued within 24 hours from randomization. For individuals with active orders for more than one targeted agent, cessation of any will be adequate to meet this endpoint. |
| Secondary | 14- Day Mortality Rate | Assessed from date of randomization to date of death from any cause, within 14 days of randomization | Percentage of patients who expire within 14 days of randomization |
| Secondary | Inpatient Mortality Rate | Assessed from point of randomization to the date of death from any cause during the end of current index hospitalization, up to 365 days | Percentage of patients who expire during index hospitalization. |
| Secondary | Percentage of Patients Who Receive Dialysis Within 14 Days of Randomization | Assessed from point of randomization to date of first documented dialysis order, within 14 days of randomization | Receipt of hemodialysis, continuous renal replacement, or peritoneal dialysis within 14 days of randomization |
| Secondary | Percentage of Patients on Inpatient Dialysis | Assessed from point of randomization to the date of first documented dialysis order during index hospitalization, up to 365 days | Receipt of hemodialysis, continuous renal replacement, or peritoneal dialysis during index hospitalization |
| Secondary | Percentage of Patients Discharged on Dialysis | Assessed at the point of discharge from index hospitalization, up to 365 days post randomization | Active orders for dialysis at the point of discharge from the index hospitalization |
| Secondary | Percentage of Patients With AKI Progression From Stage 1 to Stage 2 | Assessed from date of randomization to date of documented AKI progression, within 14 days of randomization | Progression to stage 2 AKI, represented by a doubling of baseline creatinine levels. |
| Secondary | Percentage of Patients With AKI Progression From Stage 2 to Stage 3 | Assessed from date of randomization to date of documented AKI progression, within 14 days of randomization | Progression to stage 3 AKI, represented by a tripling of baseline creatinine levels. |
| Secondary | AKI Duration | Assessed from the point of randomization to the point of AKI cessation during index hospitalization, up to 365 days | Time in hours between AKI onset and AKI cessation during index hospitalization |
| Secondary | Readmission Rate | Within 30 days of index hospitalization discharge | Number of readmissions within 30 days of discharge from index hospitalization |
| Secondary | Index Hospitalization Cost | Assessed from point of randomization to the date of discharge from index hospitalization, up to 365 days post randomization | Total cost of index hospitalization |
| Secondary | Percentage of AKI "Best Practices" Achieved Per Subject During Index Hospitalization | Assessed from 24 hours from randomization up to discharge of index hospitalization | Best practices assessed include: Avoidance of nephrotoxins (cessation of order or absence of de novo order of IV constrast agent, aminoglycoside, NSAID, or ACE inhibitor within 24 hours of randomization), fluid administration (administration of fluids within 24 hours of randomization), urinalysis order (with or without microscopy within 24 hours of randomization), documentation of AKI (by ICD-9 and ICD-10 codes during index hospitalization), monitoring of creatinine (at least one serum creatinine measurement occurring within 36 hours of randomization), documentation of urine output (within 24 hours of randomization), renal consult order during index hospitalization. Each metric above is binary. Outcome is reported as a composite best practice outcome representing the proportion of best practices achieved per subject. |
| Secondary | Percentage of Subjects With Chart Documentation of AKI | Assessed from time of randomization through to date of index hospitalization discharge, up to 365 days post randomization | Percentage of subjects with chart documentation of AKI by post-discharge ICD-10 codes and by chart adjudication |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02771977/registered